Prediction of future weight change with dopamine transporter in patients with Parkinson’s disease
- 18 Downloads
Fluctuating body weight is a commonly reported nonmotor feature in patients with Parkinson’s disease (PD). We hypothesised that striatal dopamine transporter (DAT) density at the time of diagnosis might play an important role in weight regulation in patients with PD. DAT density was measured from 123I-FP-CIT single-photon emission computed tomography. Region-of-interest analyses were performed to measure the specific binding of 123I-FP-CIT to DAT, and the putamen-to-caudate nucleus ratio (PCR) was calculated. Body weight was measured at baseline (W0) and at 48 months (W48). We classified subjects into three groups: weight loss, stable, and weight gain. In final analyses, 163 patients (106 men, 57 women) were included. PCR significantly differed by group in men, but not in women or across all patients. In men, PCR was slightly negatively associated with the percentage change in weight. No such correlation was found across all patients or in women. In univariate and multivariate logistic regression analyses, low PCR was associated with future weight gain in men with PD but not in women. In conclusion, striatal DAT availability at the time of diagnosis could predict subsequent weight change in men with PD.
KeywordsParkinson’s disease Dopamine plasma membrane transport proteins Neuroimaging Obesity
PPMI, a public–private partnership, is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including AbbVie, Avid, Biogen, Bristol-Myers Squibb, COVANCE, GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Lilly, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, TEVA, and UCB. This work was supported by a 2-Year Research Grant of Pusan National University.
- Balestrino R, Baroncini D, Fichera M, Donofrio CA, Franzin A, Mortini P, Comi G, Volonte MA (2017) Weight gain after subthalamic nucleus deep brain stimulation in Parkinson’s disease is influenced by dyskinesias’ reduction and electrodes’ position. Neurol Sci 38(12):2123–2129. https://doi.org/10.1007/s10072-017-3102-7 CrossRefGoogle Scholar
- Conover W (1999) Practical Nonparametric Statistics, 3rd edn. Wiley, HobokenGoogle Scholar
- Crandall CJ, Yildiz VO, Wactawski-Wende J, Johnson KC, Chen Z, Going SB, Wright NC, Cauley JA (2015) Postmenopausal weight change and incidence of fracture: post hoc findings from Women’s Health Initiative Observational Study and Clinical Trials. BMJ 350:h25. https://doi.org/10.1136/bmj.h25 CrossRefGoogle Scholar
- Garcia-Gomez FJ, Garcia-Solis D, Luis-Simon FJ, Marin-Oyaga VA, Carrillo F, Mir P, Vazquez-Albertino RJ (2013) Elaboration of the SPM template for the standardization of SPECT images with 123I-Ioflupane. Rev Esp Med Nucl Imagen Mol 32(6):350–356. https://doi.org/10.1016/j.remn.2013.02.009 Google Scholar
- Gupta A, Mayer EA, Hamadani K, Bhatt R, Fling C, Alaverdyan M, Torgerson C, Ashe-McNalley C, Van Horn JD, Naliboff B, Tillisch K, Sanmiguel CP, Labus JS (2017) Sex differences in the influence of body mass index on anatomical architecture of brain networks. Int J Obesity 41(8):1185–1195. https://doi.org/10.1038/ijo.2017.86 CrossRefGoogle Scholar
- Lee JJ, Oh JS, Ham JH, Lee DH, Lee I, Sohn YH, Kim JS, Lee PH (2016) Association of body mass index and the depletion of nigrostriatal dopamine in Parkinson’s disease. Neurobiol Aging 38:197–204. https://doi.org/10.1016/j.neurobiolaging.2015.11.009 CrossRefGoogle Scholar
- Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, Lee CS, McKenzie J, McCormick S, Samii A, Troiano A, Ruth TJ, Sossi V, de la Fuente-Fernandez R, Calne DB, Stoessl AJ (2009) Longitudinal progression of sporadic Parkinson’s disease: a multi-tracer positron emission tomography study. Brain 132(Pt 11):2970–2979. https://doi.org/10.1093/brain/awp209 CrossRefGoogle Scholar
- Oh M, Kim JS, Kim JY, Shin KH, Park SH, Kim HO, Moon DH, Oh SJ, Chung SJ, Lee CS (2012) Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med 53(3):399–406. https://doi.org/10.2967/jnumed.111.095224 CrossRefGoogle Scholar
- Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15(1):273–289. https://doi.org/10.1006/nimg.2001.0978 CrossRefGoogle Scholar
- Wills AM, Perez A, Wang J, Su X, Morgan J, Rajan SS, Leehey MA, Pontone GM, Chou KL, Umeh C, Mari Z, Boyd J (2016) Association between change in body mass index, Unified Parkinson’s Disease Rating Scale Scores, and survival among persons with Parkinson disease: secondary analysis of longitudinal data from NINDS Exploratory Trials in Parkinson Disease Long-term Study 1. JAMA Neurol 73(3):321–328. https://doi.org/10.1001/jamaneurol.2015.4265 CrossRefGoogle Scholar
- Yager LM, Garcia AF, Wunsch AM, Ferguson SM (2015) The ins and outs of the striatum: role in drug addiction. Neuroscience 301:529–541. https://doi.org/10.1016/j.neuroscience.2015.06.033 CrossRefGoogle Scholar